Back to Main

Faculty Detail    
Name UPENDER MANNE
Director, Translational Anatomic Pathology
 
Campus Address WTI 420A Zip 3300
Phone  (20-5) -276
E-mail  upendermanne@uabmc.edu
Other websites Google Scholar
Research Gate
     


Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Pathology   Anatomic Pathology Professor
Secondary  Surgery   Surgery - Gen Surg Gastrointestinal Section Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Professor
Center  General Clinical Research Center  Minority Health & Research Center Professor
Center  Nutrition Sciences   Nutrition Obesity Res Ctr (NORC) Professor

Graduate Biomedical Sciences Affiliations
Cancer Biology 
Integrative Biomedical Sciences 
Medical Scientist Training Program 
Molecular and Cellular Pathology Program 
Pathobiology and Molecular Medicine 

Biographical Sketch 
Dr. Manne obtained his M.S. (Biochemistry, Histochemistry, Parasitology, Zoonosis) and Ph.D. (energy metabolic pathways of endoparasites) degrees from Osmania University, Hyderabad, India. His postdoctoral training was in molecular immunology and vaccine development for malaria (Malaria Research Center, Delhi, India); in helicobacter infections (School of Microbiology, University of New South Wales, Sydney, Australia); and in histopathology, molecular tumor biology, and preclinical translational research of human malignancies at the University of Alabama at Birmingham (UAB). He also received certification in bioinformatics at UAB. Dr. Manne’s research on racial disparity in CRC has received considerable national and international recognition. In 2009, the Presidents Cancer Panel invited Dr. Manne to speak on “Biologic differences between ethnic groups and their clinical implications in cancer care,” and devoted to the topic, “America’s demographic and cultural transformation: implications for the cancer enterprise.” Currently, he is the Lead Principal Investigator of two Comprehensive Cancer Research Partnership between UAB Comprehensive Cancer Center and Tuskegee University, Tuskegee, AL and Morehouse School of Medicine, Atlanta, GA (U54); and Alabama State University, Montgomery, AL (P20) to Reduce Cancer Health Disparities by implementing innovative, multi-disciplinary, collaborative, population-based cancer control and prevention research and has contributed to education, training, and community outreach activities. These two programs are funded by the National Cancer Institute of the National Institute of Health.

Society Memberships
Organization Name Position Held Org Link
American Society of Clinical Oncology  Active member   
American Association for Cancer Research  Active member   



Research/Clinical Interest
Title
Translational research in grastrointestinal malignancies and breast cancer
Description
Dr. Manne’s present efforts are focused on population-based translational research for human neoplasias, with emphasis on colorectal and breast cancers. His laboratory, with projects funded by the National Cancer Institute and the Susan G. Komen Foundation, is evaluating molecular markers to identify aggressive phenotypic features of tumors to predict the efficacy of chemotherapeutic regimens and to assess clinical outcomes. Dr. Manne’s research and collaborative groups include experts in the fields of molecular biology, clinical oncology, pathology, epidemiology, statistics, and bioinformatics. For evaluating the clinical utility of genetic and phenotypic abnormalities in colorectal cancer, his group has developed strategies demonstrating that the utility of molecular biomarkers varies according to the anatomic location of tumors within the colorectum and with tumor stage, race/ethnicity, age, and gender. To validate the clinical utility of genetic and phenotypic markers, Dr. Manne’s laboratory is evaluating hundreds of colorectal cancer samples derived from African American and non-Hispanic Caucasian ethnic/racial backgrounds and collected from different institutions. Established molecular markers with be merged with other epidemiological, environmental, and socio-economic features to find the basis for racial disparities in colorectal and breast malignancies. Results from approaches involving biomarker discovery and bioinformatics will aid in developing predictive models specific for individual patients. The research interests of Dr. Manne also include use of genomics and proteomics for identification of early markers of cancers, specifically, identification of molecular signatures of benign colonic epithelium, which is at risk of developing colorectal neoplasias, and of other pre-malignant lesions. These studies will aid in the evaluation of molecular and pathologic characteristics of specimens and in the development of assays that relate to early detection, diagnosis, prognosis, and treatment of cancers.

Selected Publications 
Publication PUBMEDID
Agarwal S, Chakravarthi BVSK, Behring M, Kim HG, Chandrashekar DS, Gupta N, Bajpai P, Elkholy A, Balasubramanya SAH, Hardy C, Diffalha SA, Varambally S, Manne U. PAICS, a Purine Nucleotide Metabolic Enzyme, is Involved in Tumor Growth and the Metastasis of Colorectal Cancer. Cancers (Basel). 2020 Mar 25;12(4). pii: E772. doi: 10.3390/cancers12040772.  32218208 
Agarwal S, Behring M, Kim HG, Bajpai P, Chakravarthi BVSK, Gupta N, Elkholy A, Al Diffalha S, Varambally S, Manne U. Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model. Transl Oncol. 2020 Mar 18;13(4):100754. doi: 10.1016/j.tranon.2020.  32199274 
Chandrashekar DS, Chakravarthi BVSK, Robinson AD, Anderson JC, Agarwal S, Balasubramanya SAH, Eich ML, Bajpai AK, Davuluri S, Guru MS, Guru AS, Naik G, Della Manna DL, Acharya KK, Carskadon S, Manne U, Crossman DK, Ferguson JE, Grizzle WE, Palanisamy N, Willey CD, Crowley MR, Netto GJ, Yang ES, Varambally S, Sonpavde G. Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. Oncogene. 2020 Mar 30. doi: 10.1038/s41388-020-1275-7.  32231273 
Mittal K, Toss MS, Wei G, Kaur J, Choi DH, Melton BD, Osan RM, Miligy IM, Green AR, Janssen EAM, Søiland H, Gogineni K, Manne U, Rida P, Rakha EA, Aneja R. A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma In Situ.Clin Cancer Res. 2020 Jan 14. doi: 10.1158/1078-0432.CCR-19-1272.  31937618 
Behring M, Hale K, Ozaydin B, Grizzle WE, Sodeke SO, Manne U. Inclusiveness and ethical considerations for observational, translational, and clinical cancer health disparity research. Cancer. 2019 Sep 10. doi: 10.1002/cncr.32495.   31502259 
Behring M, Vazquez AI, Cui X, Irvin MR, Ojesina AI, Agarwal S, Manne U, Shrestha S. Gain of function in somatic TP53 mutations is associated with immune-rich breast tumors and changes in tumor-associated macrophages. Mol Genet Genomic Med. 2019 Oct 22:e1001.  31637877  
Agarwal S, Behring M, Hale K, Al Diffalha S, Wang K, Manne U, Varambally S. MTHFD1L, A Folate Cycle Enzyme, Is Involved in Progression of Colorectal Cancer. Transl Oncol. 2019 Nov;12(11):1461-1467.   31421459 
Bhattarai S, Klimov S, Mittal K, Krishnamurti U, Li XB, Oprea-Ilies G, Wetherilt CS, Riaz A, Aleskandarany MA, Green AR, Ellis IO, Cantuaria G, Gupta M, Manne U, Agboola J, Baskovich B, Janssen EAM, Callagy G, Walsh EM, Mehta A, Dogra A, Shet T, Gajaria P, Traina T, Nggada HA, Omonisi A, Ahmed SA, Rakha EA, Rida P, Aneja R. Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study. Cancers (Basel). 2019 Jul 17;11(7).   31319547 
Bedi D, Henderson HJ, Manne U, Samuel T. Induces PD-L1 and Immunomodulatory Cytokines in Colon Cancer Cells. Medicines (Basel). 2019 Apr 24;6(2).  31022845  
Hebert-Magee S, Yu H, Behring M, Jadhav T, Shanmugam C, Frost A, Eltoum IE, Varambally S, Manne U. The combined survival effect of codon 72 polymorphisms and p53 somatic mutations in breast cancer depends on race and molecular subtype. PLoS One. 2019;14(2):e0211734.  30730944 
Hasan S, Jacob R, Manne U, Paluri R. Advances in pancreatic cancer biomarkers Article. Oncology Reviews. 2019 (Feb); 13(1).  31044028 
Behring M, Shrestha S, Manne U, Cui X, Gonzalez-Reymundez A, Grueneberg A, Vazquez AI. Integrated landscape of copy number variation and RNA expression associated with nodal metastasis in invasive ductal breast carcinoma. Oncotarget. 2018;9(96):36836-36848.  30627325 
Chakravarthi BVSK, Chandrashekar DS, Hodigere Balasubramanya SA, Robinson AD, Carskadon S, Rao U, Gordetsky J, Manne U, Netto GJ, Sudarshan S, Palanisamy N, Varambally S. Wnt receptor Frizzled 8 is a target of ERG in prostate cancer. Prostate. 2018;78(16):1311-1320.  30051493 
Kouba E, Ford A, Brown CG, Yeh C, Siegal GP, Manne U, Eltoum IE. Detection of BRAF V600E Mutations With Next-Generation Sequencing in Infarcted Thyroid Carcinomas After Fine-Needle Aspiration.  29868707  
Kumar S, Gurshaney S, Adagunodo Y, Gage E, Qadri S, Sharma M, Malik S, Manne U, Singh UP, Singh R, Mishra MK. Hsp70 and gama-Semino protein as possible prognostic marker of prostate cancer. Front Biosci (Landmark Ed). 2018; 23:1987-2000.   29772540 
Kumar S, Singh R, Malik S, Manne U, Mishra M. Prostate cancer health disparities: An immuno-biological perspective. Cancer Lett. 2018;414:153-165.  29154974 
Jia X, Shanmugam C, Paluri RK, Jhala NC, Behring MP, Katkoori VR, Sugandha SP, Bae S, Samuel T, Manne U. Prognostic Value of Loss of Heterozygosity and Sub-Cellular Localization of SMAD4 Varies with Tumor Stage in Colorectal Cancer. Oncotarget, 2017; 8:20198-20212.  28423626 
Koo DH, Singh B, Jiang J, Friebe B, Gill BS, Chastain PD, Manne U, Tiwari HK, Singh KK. Single molecule mtDNA fiber FISH for analyzing numtogenesis. Anal Biochem. 2017, pii: S0003-2697(17)30131-8.   28322800 
Chakravarthi BVSK, Chandrashekar DS, Agarwal S, Balasubramanya SAH, Pathi SS, Goswami MT, Jing X, Wang R, Mehra R, Asangani IA, Chinnaiyan AM, Manne U, Sonpavde G, Netto GJ, Gordetsky J, Varambally S. miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. Mol Cancer Res. 2017, DOI: 10.1158/1541-7786.MCR-17-0230.  29025958 
Kumar S, Stokes J III , Singh UP, Scissum-Gunn K, Manne U, Mishra M. Prolonged exposure of resveratrol induces reactive superoxide species-independent apoptosis in murine prostate cells. Tumor Biology, 2017; 1-20  29065794 
Katkoori VR, Manne U, Chaturvedi L, Basson M, Haan P, Coffey D, Bumpers HL. Functional consequence of the p53 codon 72 polymorphism in colorectal cancer. Oncotarget, 2017, Aug 29;8(44):76574-76586.   29100333  
Chowdhury R, Gales D, Valenzuela P, Miller S, Yehualaeshet T, Manne U, Francia G, Samuel T. Bromoethylindole (BEI-9) redirects NF-κB signaling induced by camptothecin and TNFα to promote cell death in colon cancer cells. Apoptosis. 2017 Dec;22(12):1553-1563.  29116428 
Zhang W, Zhang B, Vu T, Yan G, Zhang B, Chen X, Manne U, Datta PK. Molecular characterization of pro-metastatic functions of ß4-integrin in colorectal cancer. Oncotarget, 2017, 27;8(54):92333-92345.   29190919  
Kaye S, Zeng Z, Sanders M, Chittur K, Koelle PM, Lindquist R, Manne U, Lin Y, Wei J. Label-Free Detection of DNA Hybridization with A Compact LSPR-based Fiber-Optic Sensor. Analyst, 2017, 142(11):1974-1981.DOI: 10.1039/C7AN00249A  28504795 
Kumar S, Stokes J III , Eroglu E, Scissum-Gunn K, Saldanha S, Singh U, Manne U, Ponnazhagan S, Mishra M. Resveratrol induces mitochondria-mediated, caspase-independent apoptosis in murine prostate cancer cells. Oncotarget, 2017; DOI: 10.18632/oncotarget.14947.  28157696 
Council LN, Shanmugam C, Suswam EA, Katkoori VR, Heslin MJ, Hanna A, Jhala NC, Varambally S, Manne U.Association between Hepatitis C Virus Infection, p53 Phenotypes, and Gene Variants of Adenomatous Polyposis Coli in Hepatocellular Carcinomas.J Dig Dis Hepatol. 2016;2016(5). pii: JDDH-121.  28203651 
Govindarajan R, Posey J, Chao CY, Lu R, Jadhav T, Javed AY, Javed A, Mahmoud FA, Osarogiagbon RU, Manne U.
A comparison of 12-gene colon cancer assay gene expression in African American and Caucasian patients with stage II colon cancer.BMC Cancer. 2016;16:368.  
27316467 
Kumar S, Stokes J 3rd, Singh UP, Scissum Gunn K, Acharya A, Manne U, Mishra M. Targeting Hsp70: A possible therapy for cancer.Cancer Lett. 2016;374(1):156-66.  26898980 
Krishna SR, Kaur S, Smith LM, Johansson SL, Jain M, Patel A, Gautam SK, Hollingsworth MA, Mandel U, Clausen H, Lo WC, Fan WL, Manne U, Batra SK. Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer. Cancer Lett. 2016. pii: S0304-3835(16)30070-2.  26898938 
Narayanan NK, Kunimasa K, Yamori Y, Mori M, Mori H, Nakamura K, Miller G, Manne U, Tiwari AK, Narayanan B. Antitumor activity of melinjo (Gnetum gnemon L.) seed extract in human and murine tumor models in vitro and in a colon-26 tumor-bearing mouse model in vivo.Cancer Med. 2015;4(11):1767-80.   26408414 
Katkoori VR, Basson MD, Bond VC, Manne U, Bumpers HL.Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial‑to‑mesenchymal transition in colon and breast cancers.Oncotarget. 2015;6(29):27763-77.   6318034 
Fadlalla K, Elgendy R, Gilbreath E, Pondugula SR, Yehualaeshet T, Mansour M, Serbessa T, Manne U, Samuel T.3-(2-Bromoethyl)-indole inhibits the growth of cancer cells and NF-κB activation.Oncol Rep. 2015;34(1):495-503.  26063116  
Bumpers HL, Janagama DG, Manne U, Basson MD, Katkoori V.Nanomagnetic levitation three-dimensional cultures of breast and colorectal cancers.J Surg Res. 2015;194(2):319-26.  25617973 
Karthikeyan C, Lee C, Moore J, Mittal R, Suswam EA, Abbott KL, Pondugula SR, Manne U, Narayanan NK, Trivedi P, Tiwari AK. IND-2, a pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline derivative, circumvents multi-drug resistance and causes apoptosis in colon cancer cells.Bioorg Med Chem. 2015;23(3):602-11.  25537531 
Putcha BD, Jia X, Katkoori VR, Salih C, Shanmugam C, Jadhav T, Bovell LC, Behring MP, Callens T, Messiaen L, Bae S, Grizzle WE, Singh KP, Manne U.Clinical Implications of Rabphillin-3A-Like Gene Alterations in Breast Cancer.PLoS One. 2015 12;10(6):e0129216.   26070152 
Samuel T, Fadlalla K, Gales DN, Putcha BD, Manne U.Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugs.BMC Cancer. 2014 Aug 18;14:599.   25134433 
Tabatabai MA, Kengwoung-Keumo JJ, Eby WM, Bae S, Manne U, Fouad M, Singh KP.A New Robust Method for Nonlinear Regression. J Biom Biostat. 2014;5(5):211  26185732 
Tabatabai MA, Li H, Eby WM, Kengwoung-Keumo JJ, Manne U, Bae S, Fouad M, Singh KP.Robust Logistic and Probit Methods for Binary and Multinomial Regression.J Biom Biostat. 2014;5(4). pii: 202.  26078914  
Tabatabai MA, Kengwoung-Keumo JJ, Eby WM, Bae S, Guemmegne JT, Manne U, Fouad M, Partridge EE, Singh KP.Disparities in cervical cancer mortality rates as determined by the longitudinal hyperbolastic mixed-effects type II model.PLoS One. 2014;9(9):e107242.   25226583  
Bovell LC, Shanmugam C, Putcha BD, Katkoori VR, Zhang B, Bae S, Singh KP, Grizzle WE, Manne U.The Prognostic Value of MicroRNAs Varies with Patient Race/Ethnicity and Stage of Colorectal Cancer.Clin Cancer Res. 2013 Jul 15;19(14):3955-65.  23719259 
McNally L, Manne U, Grizzle WE.Post-transcriptional processing of genetic information and its relation to cancer.Biotech Histochem. 2013;88(7):365-72.  23286224 
Doidge C, Crust I, Lee A, Buck F, Hazell S, Manne U: Therapeutic immunisation against helicobacter infection. LANCET,1994; 343 (8902):914-5.  7908372 
Manne U, Myers RB, Srivastava S, Grizzle WE. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J. NATL. CANCER. INST., 1997; 89(8): 585-6.  9106651 
Manne U, Myers RB, Moron C, Poczatek RB, Dillard S, Weiss HL, Brown D, Srivastava S, Grizzle WE. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. INT. J. CANCER, 1997;74(3): 346-58.  9221816 
Manne U, Weiss HL, Myers RB, Danner OK, Moron C, Srivastava S, Grizzle WE. Nuclear accumulation of p53 in colorectal adenocarcinoma: prognostic significance differs with race and location of the tumor. CANCER, 1998; 83(12): 2456-67.  9874449 
Myers RB, Oelschlager DK, Coan PN, Frost AR, Weiss HL, Manne U, Pretlow TG, Grizzle WE.
J Urol. 1999 Mar;161(3):945-9.Changes in cyclin dependent kinase inhibitors p21 and p27 during the castration induced regression of the CWR22 model of prostatic adenocarcinoma.J Urol. 1999 Mar;161(3):945-9. 
10022731 
Urban D, Myers R, Manne U, Weiss H, Mohler J, Perkins D, Markiewicz M, Lieberman R, Kelloff G, Marshall M, Grizzle W.Evaluation of biomarker modulation by fenretinide in prostate cancer patients.Eur Urol. 1999;35(5-6):429-38.  10325501 
Myers RB, Oelschlager D, Manne U, Coan PN, Weiss H, Grizzle WE.Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma. Int J Cancer. 1999 Jul 30;82(3):424-9.  10399960 
Poczatek RB, Myers RB, Manne U, Oelschlager DK, Weiss HL, Bostwick DG, Grizzle WE.Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.J Urol. 1999 Oct;162(4):1462-6.  10492238 
Piyathilake CJ, Frost AR, Weiss H, Manne U, Heimburger DC, Grizzle WE.The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung.Hum Pathol. 2000 Apr;31(4):482-7.  10821496 

Keywords
Colorectal Cancer, Breast Cancer, Molecular Biomarkers, Racial/Ethnic Disparities, Cancer Control & Prevention